FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated anti-PD-1 antibody or its antigen-binding fragment, as well as to a composition, combination and a set containing it. Also an isolated nucleic acid encoding the above antibody or a fragment thereof, as well as a vector and a cell containing it are disclosed. The invention also relates to a method of obtaining an isolated anti-PD-1 antibody or antigen-binding fragment thereof, which involves growing the above cell.
EFFECT: invention is effective for the preparation of a drug for the treatment of a tumor or cancer associated with PD-1, as well as for the treatment of a tumor or cancer associated with PD-1.
22 cl, 25 dwg, 15 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| INHIBITORY PATHWAY NEUTRALIZATION IN LYMPHOCYTES | 2017 |
|
RU2769569C2 |
| PD-1 BINDING ANTIBODIES AND METHODS OF THEIR USE | 2019 |
|
RU2812280C1 |
| ANTIBODIES BINDING TO PD-1 AND THEIR APPLICATIONS | 2019 |
|
RU2773758C2 |
| PD1 ANTIBODIES AND THEIR APPLICATION METHODS | 2016 |
|
RU2746409C1 |
| HUMANIZED ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF | 2022 |
|
RU2829508C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| STABLE COMPOSITION OF RECOMBINANT ANTI-PD-1 MONOCLONAL ANTIBODY | 2021 |
|
RU2827610C1 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
